Office of health affairs dissolves
This article was originally published in The Gray Sheet
Executive SummaryProfessional staff members from the FDA Center for Devices and Radiological Health's office of health affairs are reassigned to positions in the office of standards and regulations and the office of device evaluation following the dissolution of OHA. OHA Deputy director Thomas Arrowsmith-Lowe, MD, and staffers Peter Paras and Robert Gottesman have moved to OSR. Four staffers have moved to ODE: Kevin Mulry, DDS, to the division of general and restorative devices; Claudia Gaffey, MD, to the division of clinical laboratory devices; and Mariana Kastrinakis, MD, and Suzanne Parisian, MD, to the division of reproductive, abdominal, ENT and radiological devices. OHA Director Gordon Johnson, MD, has retired.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.